Increasing HPV Vaccination in Pediatric, Adolescent, and Young Adult (PAYA) Cancer Survivors
Study Details
Study Description
Brief Summary
The primary objectives of this study are to increase HPV vaccination initiation and 3-dose completion among pediatric, adolescent, and young adult (PAYA) cancer survivors
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
N/A |
Detailed Description
PAYA cancer survivors are 2.8 times more likely to develop a secondary human papillomavirus (HPV)-associated cancer than the general population. Unfortunately, HPV vaccination coverage among PAYA cancer survivors is even lower than that in the general population. Provision of adequate vaccine information and instructions for timing of vaccination post-treatment is associated with an increased intention to vaccinate. Nonetheless, research show a minority of cancer care teams specifically discuss HPV vaccination with PAYA cancer survivors and their caregivers. The purpose of this study is to test the efficacy of an oncologist- and clinic-level intervention and the additional effect of a patient-level app-based intervention to improve initiation and 3-dose completion of the HPV vaccine series.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: GLAm App Participants will have access to Game based Learning Avatar navigated mobile (GLAm ) app and will receive the receive the quality improvement (QI) intervention plus the GLAm app. |
Behavioral: GLAm app
Game-based Learning Avatar-navigated mobile (app) provides information on HPV infection susceptibility, risk of HPV-associated cancers, screening methods, and ways to overcome screening barriers. Users navigate the app using an avatar, and earn points for game components completed. The app prompts screening using text message reminders based on patient-entered information, and links to schedule cervical cancer screening. Completing cervical cancer screening earns an electronic badge visible to other users via an anonymous screen name and avatar.
|
| No Intervention: Usual care Participants in the control group will not receive the access to the GLAm app. They will receive the quality improvement (QI) intervention only. |
Outcome Measures
Primary Outcome Measures
- Study enrollment [within 6 months of index clinic visit]
Number of participants who complete the 3-dose HPV vaccine series within 12 months of study enrollment.
Secondary Outcome Measures
- Change in HPV and HPV vaccination knowledge pre- and post-intervention [baseline and 1 year post survivorship clinic visit]
The change in knowledge is assessed through self reported surveys administered to participants
- Number of participants intent to vaccinate against HPV [At the time of index clinic visit, baseline]
The number of participants with intent to vaccinate is assessed through self reported surveys administered to participants
- Proportion of participants intending to vaccinate initiating and completing the vaccine series [1 year post index clinic visit]
The Proportion of participants intending to vaccinate initiating and completing the vaccine series is measured through surveys and health record review
- Demographics differences associated with vaccination status [1 year post index clinic visit]
measure through health record review
- Cancer occurrences associated with vaccination status [1 year post index clinic visit]
measure through health record review
- Treatment differences associated with vaccination status [1 year post index clinic visit]
measure through health record review
- Number of participants experiencing barriers to vaccination [1 year post index clinic visit]
Survey measurement
- Number of participants using and accepting the game based learning app [1 year post index clinic visit]
Survey measurement
- Concordance between reported and documented vaccination against HPV [1 year post index clinic visit]
measured through surveys and health record review
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Current patient in the University of Minnesota CCSP clinic or the Children's Minnesota Long-Term Follow-up (LTFU) Program clinic.
-
Patients seen in the CCSP clinic who do not have a history of cancer but who have received immunosuppressive therapy or HSCT for treatment of a hematologic disorder.
-
Survivor of childhood cancer (defined as diagnosed with cancer at age 25 years or younger) who is currently 18-26 years of age OR a caregiver of a survivor of childhood cancer who is currently 9-17 years of age.
-
6+ months post-treatment; current treatment for graft-versus-host disease allowed
-
No previous HPV vaccination or incomplete HPV vaccination (defined as <3 doses post-cancer therapy). Individuals who are unsure of their HPV vaccination status who are unable to find vaccination records per the procedures detailed in Section 5.2, EHR support will be eligible, in concordance with real-world clinical practice regarding HPV vaccination.
Exclusion Criteria:
-
Previous completion of the HPV vaccination series. Those who are eligible for re-vaccination per the CDC guidelines will be encouraged by their oncologist to re-vaccinate, but will not be included in the QI study or RCT.
-
Unable to read/write in English per self-report (only applies to participants in the RCT [Aim 2]).
-
Pregnant at the time of enrollment or plans to become pregnant in the next year. Pregnancy test at the time of enrollment is not required if pregnancy not clinically suspected in concordance with clinical guidelines for HPV vaccine administration.
-
Currently receiving treatment for cancer or hematologic disorder or plan for treatment within 12 months of enrollment; treatment for graft-versus-host disease allowed.
-
Other contraindications to the HPV vaccine (e.g. history of immediate hypersensitivity reaction to any vaccine component, including yeast).
Contacts and Locations
Locations
No locations specified.Sponsors and Collaborators
- Masonic Cancer Center, University of Minnesota
Investigators
- Principal Investigator: Deanna Teoh, MD, MS, Masonic Cancer Center, University of Minnesota
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- 2021LS099